化合物C抑制了猫科冠状病毒的复制
Yeonjeong Park1, Chansoo Kim1, Yea-In Park1
1Division of Biological Science and Technology, Yonsei University, Wonju 26493, Republic of Korea.
Heliyon
|March 19, 2024
概括
化合物C (dorsomorphin) 在抑制猫科冠状病毒 (FCoV) 复制方面表现有前途. 这种抗病毒化合物减少了病毒载量和细胞损伤,为治疗FCoV感染和猫类传染性周周炎 (FIP) 提供了潜力.
科学领域:
- 兽医病毒学 兽医病毒学
- 分子病毒学分子病毒学
- 抗病毒药物发现发现
背景情况:
- 猫科冠状病毒 (FCoV) 是一种高度传染性的病毒,影响着家猫,在猫舍和家庭中感染率很高.
- 某些FCoV菌株会导致猫类传染性周周炎 (FIP),这是一种致命的疾病,没有有效的治疗方法.
- 目前对FCoV感染和FIP的治疗选择有限.
研究的目的:
- 研究C化合物 (dorsomorphin) 作为猫科冠状病毒 (FCoV) 复制的抑制剂的潜力.
- 评估C化合物在减少FCoV感染细胞中的病毒载量和细胞病变效应方面的疗效.
- 探索C化合物作为FCoV相关疾病的潜在治疗剂,包括FIP.
主要方法:
- 被猫科冠状病毒 (FCoV) 感染的细胞被用不同度的化合物C (dorsomorphin) 治疗.
- 量化了病毒斑块形成和细胞病变效应,以评估抗病毒活性.
- 用定量测试测量病毒RNA和蛋白质水平,以确定病毒复制抑制的程度.
主要成果:
- 化合物C治疗显著降低了FCoV诱导的斑块形成和感染细胞中的细胞病变效应.
- 在C组合物后,观察到病毒RNA和病毒蛋白的剂量依赖性减少.
- 这些结果表明,C化合物有效地抑制了FCoV在细胞水平上的复制.
结论:
- 化合物C (dorsomorphin) 在体外表现出对猫科冠状病毒 (FCoV) 的显著抗病毒活性.
- 该化合物的抑制病毒复制的能力表明它有可能成为FCoV感染的治疗剂.
- 对化合物C的进一步研究可能会导致对猫科传染性腹膜炎 (FIP) 和其他与FCoV相关的猫科病的新疗法.
相关概念视频
Cytomegalovirus Disease
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...


